[{"orgOrder":0,"company":"Kinea Bio","sponsor":"Solid Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Licensing Agreement","leadProduct":"KNA-155","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Kinea Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kinea Bio \/ Kinea Bio","highestDevelopmentStatusID":"4","companyTruncated":"Kinea Bio \/ Kinea Bio"}]

Find Clinical Drug Pipeline Developments & Deals by Kinea Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Kinea Bio will use Solid’s next-generation capsid, AAV-SLB101, for the development of KNA-155, an investigational dual AAV gene therapy.

                          Product Name : KNA-155

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          September 23, 2025

                          Lead Product(s) : KNA-155

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Recipient : Solid Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank